Get started
Author

Christopher Jon Matheny

Observed names: C MATHENY, C. Matheny, C.J. Matheny, Chris Matheny, Christopher J Matheny, Christopher J. Matheny, Christopher Matheny, Matheny, C.
Observed institutions: University of North Carolina at Chapel Hill, St. Jude Children's Research Hospital, University of Kentucky, Bristol-Myers Squibb (United States), GlaxoSmithKline (United States), Candel Therapeutics (United States)
ORCID: 0000-0001-7860-2173
Observed ORCID: 0000-0001-7860-2173
OpenAlex ID: A5080434800
Clinical trial links oncolytic immunoactivation to survival in glioblastoma
2023 · Alexander L. Ling, Isaac H. Solomon, et al. · Nature · 279
Pharmacokinetic and Pharmacodynamic Implications of P‐glycoprotein Modulation
2001 · Christopher J. Matheny, Matthew W. Lamb, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 224
PDF
Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers
2018 · Alexander Drilon, Romel Somwar, et al. · Cancer Discovery · 203
Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification
2015 · J. Larkin, T.A. Lohr, et al. · Osteoarthritis and Cartilage · 120
PDF
Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5
2005 · S MOULY, C MATHENY, et al. · Clinical Pharmacology & Therapeutics · 101
An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation
2009 · Sanjay Kumar, Christopher J. Matheny, et al. · Bone · 80
Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors
2019 · C. Willemien Menke-van der Houven van Oordt, Adam McGeoch, et al. · Journal of Nuclear Medicine · 78
PDF
Effect of Prototypical Inducing Agents on P-glycoprotein and Cyp3a Expression in Mouse Tissues
2004 · Christopher J. Matheny, Rabia Y. Ali, et al. · Drug Metabolism and Disposition · 68
Quantitation OF ARGS aggrecan fragments in synovial fluid, serum and urine from osteoarthritis patients
2014 · F.M. Germaschewski, C.J. Matheny, et al. · Osteoarthritis and Cartilage · 46
PDF
A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors
2021 · Hui K. Gan, Michael Millward, et al. · The Oncologist · 45
PDF
Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin
2016 · Marta Johnson, Dipal Patel, et al. · Drug Metabolism and Disposition · 45
Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice
2017 · Hasan Alsaid, Tinamarie Skedzielewski, et al. · PLoS ONE · 33
PDF
Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration
2000 · George R. Dickens, Daniel P. Wermeling, et al. · Annals of Allergy Asthma & Immunology · 23
Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study
2020 · Bruce A. Hug, Christopher J. Matheny, et al. · Clinical Therapeutics · 20
PDF
Manufacturing‐dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development
2022 · Neeltje Steeghs, Aaron R. Hansen, et al. · Clinical and Translational Science · 16
The highs and lows of translational drug development: antibody-mediated inhibition of ADAMTS-5 for osteoarthritis disease modification
2014 · J. Larkin, T. Lohr, et al. · Osteoarthritis and Cartilage · 13
Optimizing thein vitroand clinical assessment of drug interaction risk by understanding co-medications in patient populations
2013 · Jackie Bloomer, Geo Derimanov, et al. · Expert Opinion on Drug Metabolism & Toxicology · 12
Synergy of TLR4 agonist GSK1795091, an innate immune activator, with agonistic antibody against co-stimulatory immune checkpoint molecule OX40 in cancer immunotherapy.
2018 · Hua-Xin Gao, Sabyasachi Bhattacharya, et al. · Journal of Clinical Oncology · 10
300 Preclinical pharmacologic characterization of GSK2849330, a monoclonal AccretaMab® antibody with optimized ADCC and CDC activity directed against HER3
2014 · N. Clarke, C. Hopson, et al. · European Journal of Cancer · 10
ImmunoPET imaging to assess target engagement: Experience from Zr-89-anti-HER3 mAb (GSK2849330) in patients with solid tumors
2017 · Mcgeoch, A., van Oordt, C. Menke-van der Houven, et al. · Pure Amsterdam UMC · 9
Development of an ultra-sensitive assay for the determination of an aminoalkyl glucosaminide 4-phosphate, GSK1795091, in plasma to support a first time in human study
2018 · Hermes Licea-Perez, Venkatraman Junnotula, et al. · Analytical Methods · 6
First report of safety/tolerability and preliminary antitumor activity of CAN-2409 in inadequate responders to immune checkpoint inhibitors for stage III/IV NSCLC.
2022 · Charu Aggarwal, Andrew Haas, et al. · Journal of Clinical Oncology · 5
A Pilot Study of Estrogen's Effects on Bronchial Myocyte Adhesion Molecule Expression
1999 · George R. Dickens, Christopher J. Matheny, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 5
CAN-2409 plus prodrug with standard of care immune checkpoint inhibitor for patients with stage III/IV NSCLC.
2023 · Charu Aggarwal, Daniel Sterman, et al. · Journal of Clinical Oncology · 2
PDF
Evidence for reversible sequestration of morphine in rat liver
1996 · Christopher J Matheny, David R. Taft, et al. · Biochemical Pharmacology · 2
Works count: 37
Citation count: 1,455
H-index: 15
I10-index: 19
Year
Topic
Type